AdAlta Ltd

12:30 PM - 12:45 PM (PDT), Monday, June 13, 2022
AdAlta is a clinical stage drug discovery and development company leveraging its i-body (single domain antibody) platform to create novel protein therapeutics. The company has a specific focus on diseases where GPCRs are implicated, and on antibody, Fc-fusion and CAR-T/NK formats. Lead asset AD-214 is a first in class anti-fibrotic that has completed Phase I and is being prepared for Phase II studies in IPF. The company also has collaborations with GE Healthcare (PET imaging in immuno-oncology) and Carina Biotech (CAR-T).
Ticker:
1AD
Exchange:
ASX
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
AD-214, first in class anti-fibrotic
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO and Managing Director
AdAlta Pty Ltd.